A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer.

Autor: Nakamura K; Department of Radiation Oncology, Hamamatsu University School of Medicine, Handayama 1-20-1, Higashi-ku, Hamamatsu, 431-3192, Japan. nakam@hama-med.ac.jp., Nihei K; Osaka Medical and Pharmaceutical University, Osaka, Japan., Saito Y; Saitama Cancer Center, Saitama, Japan., Shikama N; Graduate School of Medicine, Juntendo University, Tokyo, Japan., Noda SE; International Medical Center, Saitama Medical University, Saitama, Japan., Hara R; Chiba Cancer Centre, Chiba, Japan., Imagumbai T; Kobe City Medical Center General Hospital, Hyogo, Japan., Mizowaki T; Kyoto University, Kyoto, Japan., Akiba T; Tokai University School of Medicine, Kanagawa, Japan., Kunieda E; Tokai University School of Medicine, Kanagawa, Japan., Someya M; Sapporo Medical University School of Medicine, Sapporo, Japan., Ohga S; Kyushu Medical Center, Fukuoka, Japan., Kawamori J; St. Luke's International Hospital, Tokyo, Japan., Kozuka T; Toranomon Hospital, Tokyo, Japan., Ota Y; Hyogo Cancer Center, Hyogo, Japan., Inaba K; National Cancer Center Hospital, Tokyo, Japan., Kodaira T; Aichi Cancer Center Hospital, Aichi, Japan., Itoh Y; Anjo Kosei Hospital, Aichi, Japan., Funakoshi K; Kyushu University Hospital, Fukuoka, Japan., Kagami Y; Showa University School of Medicine, Tokyo, Japan.
Jazyk: angličtina
Zdroj: International journal of clinical oncology [Int J Clin Oncol] 2024 Jun; Vol. 29 (6), pp. 847-852. Date of Electronic Publication: 2024 Apr 17.
DOI: 10.1007/s10147-024-02517-z
Abstrakt: Background: The aim of this multi-institutional phase II study was to confirm the safety and the potential efficacy of moderately hypofractionated intensity-modulated radiotherapy (IMRT) with prostate-based image-guidance for Japanese patients.
Methods: Patients with low- or intermediate-risk localized prostate cancer were eligible. Patients with a part of high risk (having only one of the following factors, cT3a, 20 < PSA ≤ 30, or GS = 8 or 9) were also included. Hypofractionated IMRT using daily image-guided technique with prostate matching was performed with a total dose of 70 Gy in 28 fractions. Neoadjuvant hormonal therapy for 4-8 months was mandatory for patients with intermediate or high-risk prostate cancer.
Results: From 20 institutions, 134 patients enrolled. The median follow-up was 5.16 years (range, 1.43-6.47 years). The number of patients with low, intermediate, and high-risk prostate cancer was 20, 80, and 34, respectively. The 5-year overall, biochemical failure-free, and clinical failure-free survival was 94.5%, 96.0%, and 99.2%, respectively. The 5-year biochemical failure-free survival for patients with low-, intermediate-, and high-risk disease was 94.1%, 97.4%, and 93.9%, respectively. The incidences of grade 2 gastrointestinal (GI) and genitourinary (GU) late toxicities at 5 years were 5.3% and 5.3%, respectively. There are no acute or late toxicities ≥ grade 3. Of 124 patients who were followed for up to 5 years, the grade 2 late GU or GI toxicities were 10.5% (90% confidence intervals, 6.3-16.2%, p = 0.0958).
Conclusion: The safety and efficacy of moderately hypofractionated IMRT with prostate-based image-guidance was confirmed among Japanese patients with prostate cancer.
(© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)
Databáze: MEDLINE